Advertisement

Topics

Latest "MAQUET Cardiovascular" News Stories

01:07 EST 16th November 2018 | BioPortfolio

Here are the most relevant search results for "MAQUET Cardiovascular" found in our extensive news archives from over 250 global news sources.

More Information about MAQUET Cardiovascular on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about MAQUET Cardiovascular for you to read. Along with our medical data and news we also list MAQUET Cardiovascular Clinical Trials, which are updated daily. BioPortfolio also has a large database of MAQUET Cardiovascular Companies for you to search.

Showing "MAQUET Cardiovascular" News Articles 1–25 of 3,000+

Relevant

Traditional Chinese medicine is widely used for cardiovascular disease

(Cardiovascular Innovations and Applications) In this Letter to the Editor, the authors comment on a review article which assesses the efficacy and safety of TCM for cardiovascular disease, as well as the pharmacological effects of active TCM ingredients on the cardiovascular system and potential mechanisms.


FDA Issues Recall of Maquet Datascope CARDIOSAVE Hybrid IABPs

Fluids spilled on the consoles might seep inside and corrode circuit boards or otherwise cause the intra-aortic balloon pump systems to malfunction, regulators say. News Alerts

FDA Warns of Possible Maquet/Datascope IABP Battery Failure

The company's intra-aortic balloon pumps may be at risk of shutting down while operating on its rechargeable battery system, the agency is warning clinicians. Medscape Medical News


Use of bivalirudin for anticoagulation in interventional cardiovascular procedures

(Cardiovascular Innovations and Applications) In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 149-162(14); DOI: 10.15212/CVIA.2017.0045 Zhen Ge, Jaya Chandrasekhar and Roxana Mehran from the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA consider the use of bivalirudin for anticoagu...

Multivitamins Don't Appear to Boost Cardiovascular Health

Taking a daily multivitamin is not associated with lower risk for adverse cardiovascular outcomes, according to a meta-analysis in Circulation: Cardiovascular Quality and Outcomes...

[Articles] SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure.

Researchers reveal link between autoimmune and cardiovascular disease in mice

People with autoimmune diseases such as psoriasis, lupus and rheumatoid arthritis are at high risk of developing cardiovascular disease, even though none of these conditions seem to target the cardiovascular system directly.

Omega-3 fats Supplements Effect on Cardiovascular Health: EPA and DHA has little or no effect on Mortality or Cardiovascular Health 

Omega-3 fats Supplements Effect on Cardiovascular Health: EPA and DHA has little or no effect on Mortality or Cardiovascular Health Reporter: Aviva Lev-Ari, PhD, RN   Cochrane Database Syst Rev. 2018 Jul 18;7:CD003177. doi: 10.1002/14651858.CD003177.pub3. [Epub ahead of print] Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Abdelhamid AS1, Brown TJ,...

Maquet Holding BV Co KG Strategic SWOT Analysis Review [Report Updated: 16082018] Prices from USD $125

Maquet Holding BV Co KG Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive your bus...

[Articles] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.

Albiglutide Beats Placebo for Cardiovascular Events in T2DM

THURSDAY, Oct. 4, 2018 -- For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events, according to a study published online Oct. 2 in The Lancet to coincide with the annual meeting of...

Weight Loss Drug Does Not Found to Increase Cardiovascular Events

NewsResearchers discovered a breakthrough weight loss drug that proves to be the first that demonstrates cardiovascular safety in a dedicated cardiovascular outcomes trial.

Weight Loss Drug Not Found to Increase Cardiovascular Events

NewsResearchers discovered a breakthrough weight loss drug that proves to be the first that demonstrates cardiovascular safety in a dedicated cardiovascular outcomes trial.

Relation of Nutrition with Cardiovascular Health

Reporter and Curator: Dr. Sudipta Saha, Ph.D.   A heart-healthy diet has been the basis of atherosclerotic cardiovascular disease (ASCVD) prevention and treatment for decades. The potential cardiovascular (CV) benefits of specific individual components of the “food-ome” (defined as the vast array of foods and their constituents) are still incompletely understood, and nutritional science c...

Review: Plant-based diets associated with better cardiovascular health

Vegetarian, especially vegan, diets are associated with better cardiovascular health, according to a new review published in the journal Progress in Cardiovascular Diseases.

[Comment] HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

In 2017, GlaxoSmithKline announced its intention to withdraw the glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide for commercial reasons. This announcement came before the emergence of definitive evidence regarding the cardiovascular safety and efficacy of albiglutide. In The Lancet, Adrian Hernandez and colleagues1 report results from the Harmony Outcomes trial, which showed, in 9463 ...

EuroHeartCare 2019

(European Society of Cardiology) The event to attend for Cardiovascular Nurses and Allied Professionals.EuroHeartCare is the annual Congress of the Association of Cardiovascular Nursing and Allied Professions (ACNAP) aimed at helping support healthcare professionals deliver the best care possible to patients with cardiovascular disease.

Announcing the TCT 2018 Press Conference Schedule

(Cardiovascular Research Foundation) The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and late-breaking clinical science that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will tak...

Announcing the TCT 2018 Late-Breaking Trials

(Cardiovascular Research Foundation) The Cardiovascular Research Foundation (CRF) has announced the 15 late-breaking trials and 12 late-breaking clinical science presentations that will be reported at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place Sep...

Psoriasis linked with need for cardiovascular interventions in patients with hypertension

(Wiley) Psoriasis is linked with increased risks of hypertension and cardiovascular disease, but its effect on the course of cardiovascular disease remains unknown.

Acute Cardiovascular Care 2019

(European Society of Cardiology) Acute Cardiovascular Care is the European meeting place for specialists dealing with patients in the acute setting. Learn, exchange and update your skills at the annual congress of the Acute Cardiovascular Care Association of the ESC.

AHA: Limited Health Literacy Is Barrier to Cardiovascular Care

TUESDAY, June 5, 2018 -- Limited health literacy is a barrier to cardiovascular health and prevention of cardiovascular disease (CVD), according to a scientific statement from the American Heart Association published online June 4 in...

Study finds albiglutide reduces cardiovascular events in patients with type 2 diabetes and existing cardiovascular disease

(Diabetologia) New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) and published in The Lancet shows that treatment with albiglutide (a type of drug called a glucagon-like peptide 1 receptor agonist) results in fewer cardiovascular events in people with type 2 diabetes and existing cardiovascular disease than treatment with placebo.

Getting leptin levels 'just right' may provide cardiovascular protection

(Medical College of Georgia at Augusta University) Like that famous bowl of porridge, when leptin levels are 'just right' they help protect our cardiovascular health, scientists say.This satiety hormone, made primarily by fat cells, is best known for telling our brains we are full. In obesity, leptin levels are high but the brain becomes resistant to its message and the cardiovascular system inste...

Omega-3 supplements do not protect against cardiovascular disease, meta-analysis shows

A meta-analysis of 79 trials showed that increasing long-chain omega-3 had little or no effect on death from all causes, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, stroke or arrhythmia.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks